Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant to enter the oncology race with its $1.4 billion acquisition of Point Biopharma Global, a company specializing in precise radioligand therapies for cancer. Earlier this year, Pfizer made headlines with its $43 billion acquisition of biotech company Seagen, bolstering its oncology portfolio with four approved cancer therapies. Amgen recently acquired Horizon Therapeutics for $27.8 billion. These multi-billion dollar deals underscore the rising demand for new innovative cancer treatments, creating a growing opportunity from oncology companies like Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF), MacroGenics, Inc. (NASDAQ:MGNX), Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), Mirati Therapeutics, Inc. (NASDAQ:MRTX), and Mersana Therapeutics, Inc. (NASDAQ:MRSN).

Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) is dedicated to advancing the development of next-generation vaccines and Antibody-Drug Conjugate (ADC) products using its distinctive proprietary platform.

At the core of Defence Therapeutics‘ platform is the revolutionary Accum® technology, which enables precise delivery of vaccine antigens or Antibody-Drug Conjugates (ADCs) to specific target cells while preserving their integrity. This breakthrough technology significantly enhances the effectiveness and potency of treatments for severe conditions like cancer and infectious diseases.

On October 10, Defence Therapeutics unveiled a groundbreaking peer-reviewed study in the esteemed journal, Cancer Science, showcasing the anticancer capabilities of its product, unconjugated Accum®. Designed specifically for treating established T-cell lymphoma, Accum® stands out in cancer research for its unique design, versatility, and the potential to address various cancer types.

The study revealed that Accum® initiates the death of various cancer cell lines, spanning T-cell lymphoma, colon, melanoma, and breast cancers. Additionally, Accum® prompts the internal production of reactive oxygen species and disrupts endosomal membranes within the cancer cells. Upon exposure to Accum®, these cancer cells undergo a process termed “immunogenic cell death.” The study further emphasizes the critical role of immune T cells, CD4 and CD8, in enhancing the efficiency of Accum®. Notably, when Accum® is directly administered to tumors, it synergizes with prevalent immune-checkpoint inhibitors, leading to a significant control over tumor growth.

Dr. Rafei, Defence Therapeutics’ Chief Scientific Officer, emphasized that Accum® combats cancer cells by both initiating cell death and activating the immune system. He noted the promising approach of Accum® in transitioning a tumor from “cold” to “hot”, as demonstrated in their latest findings.

“This prestigious peer-reviewed publication provides an important validation of the antitumoral properties of unconjugated Accum®,” said Sebastien Plouffe, President and CEO of Defence Therapeutics. “It also opens up a new line of investigation where more potent Accum® variants could be tested as an anti-cancer injectable.” 

For more information about Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF), please click here. 

Biopharma Companies Advancing Research on Cancer Treatments

MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company specializing in cancer treatment through innovative antibody-based therapeutics, announced  Gilead Sciences, Inc. nominated the first of two research programs using MacroGenics’ DART® and TRIDENT® platforms to create bispecific antibodies. Upon reaching a specified preclinical milestone, Gilead gains exclusive worldwide licensing rights. In line with their October 2022 agreement, Gilead will provide $15 million for the nominated bispecific research program led by MacroGenics. The agreement covers MGD024, a CD123 and CD3-binding bispecific antibody using the DART platform, and up to two more research programs. MacroGenics stands to receive up to $1.7 billion in various fees and royalties.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotech company specializing in polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, will present clinical data and trial designs for TIL therapies at the Society for Immunotherapy of Cancer’s 38th Annual Meeting in San Diego, CA, from November 1-5, 2023. The posters include: lifileucel TIL therapy’s 4-year analysis in advanced melanoma (C-144-01 study), TILs with IL-12 exhibit superior antitumor activity in vitro, and TILVANCE-301 phase 3 study of lifileucel TIL therapy with pembrolizumab vs. pembrolizumab alone in melanoma.

Sanofi, the French pharmaceutical company, is considering acquiring cancer drugmaker Mirati Therapeutics, Inc. (NASDAQ:MRTX). This potential deal comes as Mirati introduces its first product, the lung-cancer drug Krazati, resulting in a 45% surge in the San Diego-based company’s shares, valuing it at $4.2 billion. Acquiring Mirati would enhance Sanofi’s drug pipeline, reducing its reliance on Dupixent, a blockbuster asthma medication. Sanofi’s support would aid in Krazati’s commercialization, particularly as a second-line treatment for KRAS-mutated lung cancer. While the FDA granted accelerated approval for the drug, European regulators have yet to endorse it.

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a biopharmaceutical company focusing on antibody-drug conjugates (ADCs) for challenging cancers, announced that the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) failed to meet its primary endpoint. UpRi, an ADC targeting the NaPi2b protein, was developed using the Dolaflexin platform. UPLIFT, a single-arm trial for platinum-resistant ovarian cancer patients, aimed to assess the objective response rate (ORR) in NaPi2b-positive individuals (TPS ≥75%). Secondary endpoints included ORR for all patients, response duration (DOR), and safety. The trial also assessed ORR and DOR independently. 268 patients were enrolled, 141 NaPi2b-positive. Most had three prior therapies, with many receiving bevacizumab and PARP inhibitors.

Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) achieved an initial milestone in its collaboration with Orano to develop advanced radio-immunoconjugates, aiming for safer and more effective cancer therapies.

To learn more about Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF), please visit this link. 

Featured Image MegaPixl @Angellodeco

Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, Defence Therapeutics Inc. Market Jar Media Inc. has or expects to receive from Defence Therapeutics Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) ninety six thousand five hundred US dollars for 30 days (21 business days).

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding Defence Therapeutics Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Defence Therapeutics Inc.’s industry; (b) market opportunity; (c) Defence Therapeutics Inc.’s business plans and strategies; (d) services that Defence Therapeutics Inc. intends to offer; (e) Defence Therapeutics Inc.’s milestone projections and targets; (f) Defence Therapeutics Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Defence Therapeutics Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Defence Therapeutics Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Defence Therapeutics Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Defence Therapeutics Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e) Defence Therapeutics Inc.’s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; (i) stability in financial and capital markets; and (j) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Defence Therapeutics Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Defence Therapeutics Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Defence Therapeutics Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Defence Therapeutics Inc.’s business operations (e) Defence Therapeutics Inc. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, Defence Therapeutics Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Defence Therapeutics Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Defence Therapeutics Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Defence Therapeutics Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Defence Therapeutics Inc. or such entities and are not necessarily indicative of future performance of Defence Therapeutics Inc. or such entities.

8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.

• Featured News RSS feed
• Investing News RSS feed
• Daily Press Releases RSS feed
• Trading Tips RSS feed
• Investing Videos RSS feed

Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube